-
Gantenerumab is a
monoclonal antibody for the
treatment of Alzheimer's
disease being developed by Hoffmann-La
Roche pharmaceuticals.
Gantenerumab binds...
- Roche/Genentech for the
treatment of Alzheimer's disease. It is
based on
gantenerumab, an anti-amyloid
monoclonal antibody, and
using a
Brainshuttle domain...
-
Abushakra S, Hey JA,
Porsteinsson A,
Sabbagh M (August 2020). "Aducanumab,
gantenerumab, BAN2401, and ALZ-801-the
first wave of amyloid-targeting
drugs for Alzheimer's...
-
tested in
clinical trials included aducanumab, bapineuzumab, crenezumab,
gantenerumab, lecanemab, and solanezumab.
Imaging compounds,
notably Pittsburgh compound...
-
human HER2/neu
cancer Ganitumab mab
human IGF-1
receptor (CD221)
cancer Gantenerumab mab
human β-amyloid (1-40 and 1-42) Alzheimer's
disease Gatipotuzumab...
- A.; Porsteinsson, Anton; Sabbagh,
Marwan (2020-08-12). "Aducanumab,
gantenerumab, BAN2401, and ALZ-801—the
first wave of amyloid-targeting
drugs for Alzheimer's...
- ; Porsteinsson, Anton; Sabbagh,
Marwan (December 2020). "Aducanumab,
gantenerumab, BAN2401, and ALZ-801—the
first wave of amyloid-targeting
drugs for Alzheimer's...
- (INN)
ganglefene (INN)
ganirelix (INN)
ganitumab (USAN)
Ganite Gantanol gantenerumab (USAN, INN)
Gantrisin galyfilcon A (USAN)
gapicomine (INN) Garamycin...
